[go: up one dir, main page]

DK1008588T3 - 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel - Google Patents

11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel

Info

Publication number
DK1008588T3
DK1008588T3 DK98901576T DK98901576T DK1008588T3 DK 1008588 T3 DK1008588 T3 DK 1008588T3 DK 98901576 T DK98901576 T DK 98901576T DK 98901576 T DK98901576 T DK 98901576T DK 1008588 T3 DK1008588 T3 DK 1008588T3
Authority
DK
Denmark
Prior art keywords
derivatives
processes
preparation
active ingredient
pharmaceutical compositions
Prior art date
Application number
DK98901576T
Other languages
English (en)
Inventor
Shuichi Ono Pharm Co Ohuchida
Takayuki Ono Pharm Co Maruyama
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of DK1008588T3 publication Critical patent/DK1008588T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98901576T 1997-02-10 1998-02-10 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel DK1008588T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4157197 1997-02-10
PCT/JP1998/000544 WO1998034916A1 (fr) 1997-02-10 1998-02-10 Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif

Publications (1)

Publication Number Publication Date
DK1008588T3 true DK1008588T3 (da) 2003-07-28

Family

ID=12612138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98901576T DK1008588T3 (da) 1997-02-10 1998-02-10 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel

Country Status (10)

Country Link
US (1) US6288119B1 (da)
EP (1) EP1008588B1 (da)
JP (1) JP4044967B2 (da)
KR (1) KR20000070903A (da)
AT (1) ATE237587T1 (da)
DE (1) DE69813571T2 (da)
DK (1) DK1008588T3 (da)
ES (1) ES2196527T3 (da)
PT (1) PT1008588E (da)
WO (1) WO1998034916A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU2003272962A1 (en) * 2002-10-10 2004-05-04 Shuh Narumiya Remedies for allergic diseases
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
WO2004074842A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3)
WO2004089411A1 (ja) * 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
US7833995B2 (en) * 2003-12-05 2010-11-16 Ono Pharmaceutical Co., Ltd. Blood flow promoters for cauda equina tissues
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AU2006253356B2 (en) 2005-06-03 2011-12-01 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
JP2009505973A (ja) 2005-08-09 2009-02-12 アステランド ユーケイ リミテッド Ep2受容体アゴニスト
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
CA2665698A1 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
MX2009003875A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3'-indol)-2' (1'h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor.
WO2009065081A2 (en) 2007-11-14 2009-05-22 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2350091B1 (en) * 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN102803239B (zh) 2009-06-10 2015-04-15 小野药品工业株式会社 具有膀胱排尿肌收缩活性和尿道括约肌舒张活性的化合物
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
EP2891651B1 (en) 2012-08-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Amine salt and crystals thereof
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2818484A1 (en) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
JP7145154B2 (ja) 2016-12-09 2022-09-30 セルタクシー、エルエルシー ロイコトリエンa4ヒドロラーゼの阻害剤
EP3551611A1 (en) 2016-12-09 2019-10-16 Celtaxsys Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
AU2017371362A1 (en) 2016-12-09 2019-07-25 Celltaxis, Llc Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835180A (en) * 1971-05-04 1974-09-10 Upjohn Co 15 alkoxy pge compounds
US3876690A (en) * 1973-05-11 1975-04-08 American Cyanamid Co 1-alkoxy-9-keto-prostenoic acid derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
US4236027A (en) * 1977-10-17 1980-11-25 American Cyanamid Company Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same
JPS55115836A (en) * 1979-03-02 1980-09-06 Toray Ind Inc Preparation of methyl ether derivative
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤

Also Published As

Publication number Publication date
DE69813571T2 (de) 2004-02-12
EP1008588B1 (en) 2003-04-16
DE69813571D1 (de) 2003-05-22
PT1008588E (pt) 2003-09-30
EP1008588A4 (en) 2000-06-14
EP1008588A1 (en) 2000-06-14
KR20000070903A (ko) 2000-11-25
US6288119B1 (en) 2001-09-11
ATE237587T1 (de) 2003-05-15
ES2196527T3 (es) 2003-12-16
JP4044967B2 (ja) 2008-02-06
WO1998034916A1 (fr) 1998-08-13

Similar Documents

Publication Publication Date Title
DK1008588T3 (da) 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
PT1263730E (pt) Derivados amina para o tratamento de apoptose
NO20034660L (no) Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater
PL396946A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
DK1246809T3 (da) 5-aryl-1H-1,2,4-triazolforbindelser som inhibitor for cyclooxygenase-2 og farmaceutiske sammensætninger som indeholder dem
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
NO20045042L (no) 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60025616D1 (de) Isoindolderivate
IL136100A (en) Biphenylamidine derivatives and pharmaceutical compositions containing the same
NO20054787D0 (no) Indenderivater som farmasotiske midler
DK0884051T3 (da) Cancröse metastaseinhibitorer indeholdende uracilderivater
GB0223232D0 (en) Chemical compounds
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
ATE218560T1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
NO996284L (no) Nye imidazolinforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
NO20023363L (no) Kondenserte pyrrolforbindelser, farmasöytiske midler som inneholder dem, og anvendelse derav
NO983217D0 (no) Terapeutiske anti-astmamidler som inneholder selenforbindeler
GB0223234D0 (en) Chemical compounds
DK0412015T3 (da) Hidtil ukendte N-(23-vincristinoyl)- og N-(5-noranhydro-23-vinblastinoyl)-1-aminomethylphosphon- syrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
EP1118327A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENTS FOR THE TREATMENT OF SINUSITIS.
DK0823254T3 (da) Hidtil ukendt anvendelse af pyrazolopyridinforbindelser